BC
LAB icon

Bridgefront Capital’s Standard BioTools LAB Stock Holding History

Bridgefront Capital’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-27,023
Closed -$122K – 766
2021
Q1 		$122K Buy
27,023
+6,922
+34% +$38K 0.04% 613
2020
Q4 		$121K Buy
+20,101
New +$132K 0.04% 557

Other funds holding LAB

ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bridgefront Capital's LAB Position: Q2 2021 in Review

Bridgefront Capital sold out of Standard BioTools (LAB) in Q2 2021, closing a stake of 27,023 shares — an estimated $122K sold.

Bridgefront Capital first reported a position in LAB in Q4 2020 and held it in 2 quarters. The position peaked at $122K in Q1 2021. 113 funds tracked by Wall St. Rank hold LAB as of Q2 2021.

  • Bridgefront Capital reported no remaining Standard BioTools position as of Q2 2021 after selling out during the quarter.
  • Bridgefront Capital sold 27,023 Standard BioTools shares in Q2 2021, an estimated $122K.
  • Bridgefront Capital first reported a position in Standard BioTools in Q4 2020 and held it in 2 quarters.
  • Bridgefront Capital's Standard BioTools position peaked at $122K in Q1 2021.
  • 113 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2021.

Based on Bridgefront Capital's 13F filing for Q2 2021, filed 12 Aug 2021.